TMED2 Induces Cisplatin Resistance in Breast Cancer via Targeting the KEAP1-Nrf2 Pathway

Abstract

Objective

Cisplatin is the first-line treatment for breast cancer, but it faces challenges of drug resistance. This study investigated new molecular mechanisms underlying cisplatin resistance in breast cancer.

Methods

We analyzed sequencing data from the TCGA database to identify potential associations between transmembrane emp24 protein transport domain containing 2 (TMED2) and breast cancer. Western blotting, real-time PCR, CCK-8, and TUNEL assays were used to measure the effects and molecular mechanism of TMED2 on cisplatin resistance in MCF-7 and MDA-MB-231 cell lines.

Results

TMED2 was overexpressed in breast cancer and associated with poor prognosis. TMED2 increased cisplatin resistance in breast cancer cells in vitro via promoting ubiquitination of Kelch-like ECH-associated protein 1 (KEAP1), relieving inhibition of KEAP1 on nuclear factor erythroid 2-related factor 2 (Nrf2), and increasing expression of downstream drug resistance related genes, such as heme oxygenase 1 (HO-1) and NAD (P) H quinone oxidoreductase 1 (NQO1).

Conclusion

We identified a new molecular mechanism by which TMED2 affects cisplatin resistance in breast cancer. Our results provide theoretical guidance for future clinical applications.

Keywords

TMED2 / KEAP1 / Nrf2 / cisplatin resistance / breast cancer

References

[1] EllisLM, HicklinDJ. Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin Cancer Res, 2009, 15(24): 7471-7478

[2] DeSantisCE, FedewaSA, GodingSA, et al.. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin, 2016, 66(1): 31-42

[3] BrownAK, KumarS, TchounwouPB. Cisplatin-Based Chemotherapy of Human Cancers. J Cancer Sci Ther, 2019, 11(4): 97

[4] CangiMG, CukorB, SoungP, et al.. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest, 2000, 106(6): 753-761

[5] Van JaarsveldMT, WoutersMD, BoersmaAW, et al.. DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivity. Mol Oncol, 2014, 8(3): 458-468

[6] LeeY, AhnC, HanJ, et al.. The nuclear RNase III Drosha initiates microRNA processing. Nature, 2003, 425(6956): 415-419

[7] RongL, GuangxiY, MinB, et al.. STAMBPL1 promotes breast cancer cell resistance to cisplatin partially by stabilizing MKP-1 expression. Oncogene, 2022, 41(16): 2265-2274

[8] LiJ, XuXQ, PengXT. NDC80 Enhances Cisplatin-resistance in Triple-negative Breast Cancer. Arch Med Res, 2022, 53(4): 378-387

[9] ZengJ, WuYX, RenC, et al.. Therapeutic base editing of human hematopoietic stem cells. Nat Med, 2020, 26(4): 535-541

[10] ZengJ, WuYX, BenjaminPR, et al.. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med, 2019, 25(5): 776-783

[11] SialN, SaeedS, AhmadM, et al.. Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer. Int J Gen Med, 2021, 14: 7025-7042

[12] LinX, LiuJ, HuSF, et al.. Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer. Cancer Manag Res, 2019, 11: 2203-2214

[13] FangZ, SongYX, WoGQ, et al.. Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer. Ann Transl Med, 2022, 10(23): 1280

[14] GhareghomiS, Habibi-RezaeiM, AreseM, et al.. Nrf2 Modulation in Breast Cancer. Biomedicines, 2022, 10(10): 2668

[15] PanieriE, BuhaA, Telkoparan-AkillilarP, et al.. Potential Applications of NRF2 Modulators in Cancer Therapy. Antioxidants (Basel), 2020, 9(3): 193

[16] ParamasivanP, KankiaIH, LangdonSP, et al.. Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies. Cancer Drug Resist, 2019, 2(3): 490-515

[17] OzakiT, NakamuraM, ShimozatoO. Novel Implications of DNA Damage Response in Drug Resistance of Malignant Cancers Obtained from the Functional Interaction between p53 Family and RUNX2. Biomolecules, 2015, 5(4): 2854-2876

[18] VodickaP, AnderaL, OpattovaA, et al.. The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction. Cancers (Basel), 2021, 13(3): 479

[19] EmranTB, ShahriarA, MahmudAR, et al.. Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. Front Oncol, 2022, 12: 891652

[20] GalluzziL, SenovillaL, VitaleI, et al.. Molecular mechanisms of cisplatin resistance. Oncogene, 2012, 31(15): 1869-1883

[21] MiH, WangX, WangF, et al.. SNHG15 Contributes To Cisplatin Resistance In Breast Cancer Through Sponging miR-381. Onco Targets Ther, 2020, 13: 657-666

[22] TsangJYS, TseGM. Molecular classification of breast cancer. Adv Anat Pathol, 2020, 27(1): 27-35

[23] LiY, LiuL, LvY, et al.. Silencing long non-coding RNA HNF1A AS1 inhibits growth and resistance to TAM of breast cancer cells via the microRNA-363/SERTAD3 axis. J Drug Target, 2021, 29(7): 742-753

[24] O’DriscollL, ClynesM. Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets, 2006, 6(5): 365-384

[25] RezaieE, AmaniJ, BidmeshkiPA, et al.. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency. Eur J Pharmacol, 2020, 870: 172912

[26] PortF, HausmannG, BaslerK. A genome-wide RNA interference screen uncovers two p24 proteins as regulators of Wingless secretion. EMBO Rep, 2011, 12(11): 1144-1152

[27] D’ArcangeloJG, CrissmanJ, PagantS, et al.. Traffic of p24 proteins and COPII coat composition mutually influence membrane scaffolding. Curr Biol, 2015, 25(10): 1296-1305

[28] NagaeM, HirataT, Morita-MatsumotoK, et al.. 3D structure and interaction of p24β and p24δ Golgi dynamics domains: implication for p24 complex formation and cargo transport. J Mol Biol, 2016, 428(20): 4087-4099

[29] DenzelA, OttoF, GirodA, et al.. The p24 family member p23 is required for early embryonic development. Curr Biol, 2000, 10(1): 55-58

[30] WangHB, XiaoLQ, KazanietzMG. p23/Tmp21 Associates with protein kinase c delta (PKCδ) and modulatesits apoptotic function. J Biol Chem, 2011, 286(18): 15821-15831

[31] ZhangXJ, WuYL, CaiF, et al.. A Novel Alzheimer-Associated SNP in Tmp21 Increases Amyloidogenesis. Mol Neurobiol, 2018, 55(3): 1862-1870

[32] HouW, GuptaS, BeauchampMC, et al.. Non-alcoholic Fatty Liver Disease in Mice with Heterozygous Mutation in TMED2. PLoS One, 2017, 12(8): e0182995

[33] FengLH, ChengPJ, FengZY, et al.. Transmembrane p24 trafficking protein 2 regulates inflammation through the TLR4/NF-κ B signalingpathway in lung adenocarcinoma. World J Surg Oncol, 2022, 20(1): 32

[34] DuquentA, MelottiA, MishraS, et al.. A novel genome-wide in vivo screen for metastatic suppressors in human colon cancer identifies the positive WNT-TCF pathway modulators TMED3 and SOX12. EMBO Mol Med, 2014, 6(7): 882-901

[35] YangZ, SunQ, GuoJ, et al.. GRSF1-mediated MIR-G-1 promotes malignant behavior and nuclear autophagy by directly upregulating TMED5 and LMNB1 in cervical cancer cells. Autophagy, 2019, 15: 668-685

[36] GongSP, ChenCL, WuH, et al.. TMED2 promotes epithelial ovarian cancer growth. Oncotarget, 2017, 8(55): 94151-94165

[37] GeXL, JiangW, JiangYJ, et al.. Expression and Importance of TMED2 in Multiple Myeloma Cells. Cancer Manag Res, 2020, 12: 12895-12903

[38] FangZ, SongYX, WoGQ, et al.. Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer. Ann Transl Med, 2022, 10(23): 1280

[39] DempkeWCM, ReckM. KEAP1/NRF2 (NFE2L2) mutations in NSCLC–fuel for a superresistant phenotype?. Lung Cancer, 2021, 159: 10-17